Am J Transplant, Volume 19, Suppl 3 Archives - Page 66 of 214 - ATC Abstracts

2019 American Transplant Congress
Withaferin A as a Possible Therapy for Chronic Allograft Nephropathy
T. Divanyan¹, D. Patel¹, E. Acosta¹, D. Howard², F. Jourd'heuil², D. Jourd'heuil², R. Lopez-Soler³
¹Albany Medical College, Albany, NY, ²Molecular and Cellular Physiology, Albany Medical College, Albany, NY, ³Surgery, Section of Transplantation, Albany Medical College, Albany, NY
*Purpose: One of the possible steps in the development of post-transplant interstitial fibrosis is epithelial to mesenchymal transition (EMT) of proximal renal tubular cells with…
2019 American Transplant Congress
Galectin-3 Levels Are Associated with the Incidence and Severity of Chronic GVHD One Year after Allogeneic Hematopoietic Cell Transplantation
N. Navarro-Alvarez¹, A. R. Andrews¹, Z. DeFilipp², Y. A. Chen², V. T. Ho³, J. Ritz³, T. R. Spitzer⁴, C. A. Huang⁵
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, ³Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, ⁴Hematology/Oncology, Massachusetts General Hospital, Boston, MA, ⁵Plastic & Reconstructive Surgery and Transplant Surgery Divisions, University of Colorado, Denver, Aurora, CO
*Purpose: Chronic graft-versus-host disease (cGVHD) is a frequent complication of allogeneic hematopoietic cell transplantation (HCT) and a leading cause of late morbidity and mortality. T-…
2019 American Transplant Congress
The Polish Troubled Kidney Transplant Biopsy Study: External Validation of the Molecular Microscope System
M. Myślak¹, D. Deborska-Materkowska², M. Ciszek², J. Mazurkiewicz¹, A. Debska-Slizien³, P. F. Halloran⁴, A. Perkowska-Ptasińska⁵
¹Pomeranian Medical University, Szczecin, Poland, ²Warsaw Medical Univeristy, Warsaw, Poland, ³Gdansk Medical University, Gdansk, Poland, ⁴Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton AB, AB, Canada, ⁵Medical University of Warsaw, Warsaw, Poland
*Purpose: The transplant clinician frequently encounters kidney transplant biopsies that are difficult to interpret by histology. A Molecular Microscope Diagnostic System (MMDx) has been developed…
2019 American Transplant Congress
Urine Uromodulin Associates with Deceased Donor Acute Kidney Injury and Allograft Failure
S. G. Mansour¹, I. Hall², P. Reese³, T. Ashkar⁴, Y. Jia⁴, H. Thiessen-Philbrook⁴, M. Doshi⁵, C. R. Parikh⁴
¹Yale, New Haven, CT, ²University of Utah, Salt Lake City, UT, ³Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Johns Hopkins University, Baltimore, MD, ⁵University of Michigan, Ann Arbor, MI
*Purpose: Produced exclusively by renal epithelial cells of the thick ascending limb, Uromodulin (UMOD, also known as Tamm-Horsfall protein) is the major component of hyaline…
2019 American Transplant Congress
Evidence to Support the Use of Kidney Allograft Function as a Clinical Trial Outcome Measure
M. Kadatz, J. Gill, S. Clark, J. S. Gill
Nephrology, University of British Columbia, Vancouver, BC, Canada
*Purpose: As a biomarker, kidney allograft function has been rejected as clinical trial outcome measure because it is not predictive of allograft survival. In this…
2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels
B. Shin, N. F. Ammerman, A. A. Vo, X. Zhang, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have recently reported successful use of Tocilizumab (TCZ), an anti-IL-6 receptor (R) monoclonal antibody, for cABMR treatment in HLA-sensitized kidney transplant (KTx) Pts.…
2019 American Transplant Congress
Impact Of The Provision Of Transplant Information On Access To First And Repeat Kidney Transplantation
S. Clark, A. Abdalla, M. Kadatz, J. Gill, J. S. Gill
Nephrology, University of British Columbia, Vancouver, BC, Canada
*Purpose: To determine whether the provision and relative impact of transplant information differs in incident ESRD patients and patients with a history of previous transplant…
2019 American Transplant Congress
Estimated vs. Actual Graft Failure and Patient Survival after Kidney Transplantation
J. Buggs¹, T. Thigpen², E. Rogers¹, A. Kumar³, V. Bowers¹
¹Tampa General Hospital, Tampa, FL, ²Wesleyan College, Macon, GA, ³University of South Florida, Tampa, FL
*Purpose: The purpose of this study was to examine the difference between the estimated and actual values of graft survival and patient survival in kidney…
2019 American Transplant Congress
The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen
R. Wolff¹, A. Nasstrom¹, C. Borscheid¹, C. Martin¹, A. Temelie¹, R. Spong², D. Keys², T. B. Dunn³
¹School of Pharmacy, MHealth U of MN Medical Center-Fairview, Mpls, MN, ²Medicine, MHealth U of MN Medical Center-Fairview, Mpls, MN, ³Surgery, U of Pennsylvania, Phila, PA
*Purpose: It is not known if an extended release formulation of tacrolimus (LCPT, Envarsus XR®) can be successfully dosed to achieve an early therapeutic trough…
2019 American Transplant Congress
Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM
C. Legendre¹, S. Berger¹, F. Oppenheimer¹, A. Wiseman¹, S. Steinberg¹, O. Viklicky¹, G. Russ¹, R. Danguilan¹, N. Basic-Jukic¹, E. Mor¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², C. Sommerer¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: mTOR inhibitors (eg, everolimus [EVR]), are thought to increase the risk of post-transplant (Tx) proteinuria (PU). Here, we assess PU onset and outcomes in…